Date published: 2025-11-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Levofloxacin-d8 (CAS 1217716-71-6)

0.0(0)
Write a reviewAsk a question

Alternate Names:
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl-d8)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid Hemihydrate
Application:
Levofloxacin-d8 is an antibiotic
CAS Number:
1217716-71-6
Molecular Weight:
369.42
Molecular Formula:
C18H12D8FN3O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Levofloxacin-d8 is a chemically modified version of levofloxacin, distinguished by the substitution of eight hydrogen atoms with deuterium, a stable and non-radioactive isotope of hydrogen. This alteration significantly contributes to the utility of Levofloxacin-d8 in research environments, particularly in the fields of analytical chemistry and environmental science. The incorporation of deuterium not only enhances the molecular stability of levofloxacin, making it less susceptible to degradation over time, but also increases its molecular weight slightly, which facilitates its identification and quantification in mass spectrometric analysis. Researchers utilize Levofloxacin-d8 primarily as an internal standard in quantitative mass spectrometry studies to ensure more accurate, precise, and reproducible measurements of the parent molecule in complex biological and environmental samples. This is critical in experiments where exact quantification is necessary to understand the dynamics of levofloxacin under various conditions. Moreover, Levofloxacin-d8 plays a pivotal role in metabolic studies, aiding in the tracing and elucidation of metabolic pathways of levofloxacin through its distinguishable isotopic pattern. These capabilities make it an essential tool in studies aiming to map out the distribution, persistence, and transformation of levofloxacin in different environmental compartments, contributing to a broader understanding of its interactions and impacts.


Levofloxacin-d8 (CAS 1217716-71-6) References

  1. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.  |  Pienaar, E., et al. 2017. PLoS Comput Biol. 13: e1005650. PMID: 28817561
  2. A simple ultra-high-performance liquid chromatography-high resolution mass spectrometry assay for the simultaneous quantification of 15 antibiotics in plasma.  |  Lefeuvre, S., et al. 2017. J Chromatogr B Analyt Technol Biomed Life Sci. 1065-1066: 50-58. PMID: 28946125
  3. Antibiotics elimination and risk reduction at two drinking water treatment plants by using different conventional treatment techniques.  |  Li, G., et al. 2018. Ecotoxicol Environ Saf. 158: 154-161. PMID: 29684745
  4. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.  |  Sarathy, J., et al. 2019. Antimicrob Agents Chemother. 63: PMID: 30803965
  5. Microscale Thermophoresis as a Screening Tool to Predict Melanin Binding of Drugs.  |  Hellinen, L., et al. 2020. Pharmaceutics. 12: PMID: 32560065
  6. Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma.  |  Zheng, X., et al. 2020. J Chromatogr B Analyt Technol Biomed Life Sci. 1158: 122397. PMID: 33091676
  7. Mechanisms of cellular retention of melanin bound drugs: Experiments and computational modeling.  |  Bahrpeyma, S., et al. 2022. J Control Release. 348: 760-770. PMID: 35738465

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Levofloxacin-d8, 1 mg

sc-280913
1 mg
$290.00